Sarepta would then have an exclusive license to the programs and take over responsibility for clinical development and commercialization. The financial terms of the deal are as follows ...

H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

This adjustment comes in the wake of Sarepta's licensing deal with Arrowhead Pharmaceuticals (NASDAQ:ARWR), which incorporates a variety of clinical and preclinical assets. Sarepta's partnership ...

The recent partnership between Sarepta and Arrowhead Pharmaceuticals (NASDAQ:ARWR), announced on November 26, has reignited significant investor interest. Following the announcement, Sarepta's ...

The recent partnership between Sarepta and Arrowhead Pharmaceuticals (NASDAQ:ARWR), announced on November 26, has reignited significant investor interest. Following the announcement, Sarepta's shares ...

The adjustment follows Sarepta's recent announcement of a licensing deal with Arrowhead Pharmaceuticals (NASDAQ:ARWR), which includes a range of clinical and preclinical assets. Sarepta's newly ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ ...